Published in Vaccine Weekly, January 9th, 2002
The trial compared treatment with Zamyl plus a standardized chemotherapy regimen against treatment with chemotherapy alone in patients who had failed to achieve complete remission with initial therapy, or who had relapsed within one year of achieving complete remission. An initial review of the data by PDL indicates that Zamyl increased the overall response rate to 43% in the Zamyl plus chemotherapy patients (n=94) from 26% in the chemotherapy alone patients (n=97) (p=0.015),...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly